Related Experiment Video
Updated: Nov 16, 2025
Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery
Published on: July 18, 2019
Convection-enhanced drug delivery for glioblastoma: a review
Randy S D'Amico1, Manish K Aghi2, Michael A Vogelbaum3
1Department of Neurological Surgery, Lenox Hill Hospital/Northwell Health, New York, NY, USA. rdamico8@northwell.edu.
Introduction:
Convection-enhanced delivery (CED) is a method of targeted, local drug delivery to the central nervous system (CNS) that bypasses the blood-brain barrier (BBB) and permits the delivery of high-dose therapeutics to large volumes of interest while limiting associated systemic toxicities. Since its inception, CED has undergone considerable preclinical and clinical study as a safe method for treating glioblastoma (GBM). However, the heterogeneity of both, the surgical procedure and the mechanisms of action of the agents studied-combined with the additional costs of performing a trial evaluating CED-has limited the field's ability to adequately assess the durability of any potential anti-tumor responses. As a result, the long-term efficacy of the agents studied to date remains difficult to assess.
Materials And Methods:
We searched PubMed using the phrase "convection-enhanced delivery and glioblastoma". The references of significant systematic reviews were also reviewed for additional sources. Articles focusing on physiological and physical mechanisms of CED were included as well as technological CED advances.
Results:
We review the history and principles of CED, procedural advancements and characteristics, and outcomes from key clinical trials, as well as discuss the potential future of this promising technique for the treatment of GBM.
Conclusion:
While the long-term efficacy of the agents studied to date remains difficult to assess, CED remains a promising technique for the treatment of GBM.
